Nyrada Inc
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
stocks
ASX energy giant undervalued despite commissioning challenges
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,198.30 | 29.30 | 0.32% |
| CAC 40 | 8,458.78 | 52.72 | 0.63% |
| DAX 40 | 25,464.01 | 102.98 | 0.41% |
| Dow JONES (US) | 52,747.32 | 537.24 | 1.03% |
| FTSE 100 | 10,871.02 | 89.27 | 0.83% |
| HKSE | 25,625.38 | 314.53 | 1.24% |
| NASDAQ | 24,876.91 | 55.17 | -0.22% |
| Nikkei 225 | 61,299.40 | 1,065.52 | -1.71% |
| NZX 50 Index | 13,976.67 | 114.74 | 0.83% |
| S&P 500 | 7,428.78 | 15.60 | 0.21% |
| S&P/ASX 200 | 9,036.60 | 33.10 | 0.37% |
| SSE Composite Index | 3,831.08 | 17.77 | 0.47% |